Bioeclosion highlights next-generation biosensor innovation at 4YFN-MWC 2026 with stand presence and investor pitch

Showcasing its technology at the UAB stand and selected to pitch at the BKA Pitch Corner, Bioeclosion presented its portable diagnostic device to investors, partners, and innovation stakeholders at Europe’s leading startup event.

Barcelona, March 2026 — Bioeclosion participated in 4YFN-MWC 2026, the startup event held within the Mobile World Congress programme in Barcelona, where the company showcased its next-generation biosensor technology at the Universitat Autònoma de Barcelona (UAB) stand, 8.1C43, in the University & Spin-offs area. Bioeclosion was also selected to present at the BKA Pitch Corner on 3 March, further strengthening its visibility among investors, industry stakeholders, and potential partners across the deep-tech ecosystem.

During the event, Bioeclosion presented its portable in vitro diagnostic device, developed in collaboration with Eurecat and exhibited at both the Bioeclosion/UAB stand and the Eurecat stand during MWC 2026. Designed as a compact “pocket laboratory,” the device is based on high-sensitivity magnetically actuated electrochemical biosensors and is capable of delivering robust, quantitative results from small sample volumes in approximately 10 minutes.

The portable diagnostic device was developed within the framework of the EChiLiBRiST project, a Horizon Europe-funded initiative focused on advancing biomarker-based tools for risk stratification and triage in paediatric fever syndromes. Within this context, Bioeclosion’s technology contributes to the broader goal of enabling rapid, actionable testing closer to the point of need, supporting more accessible and decentralized healthcare models.

The platform has been designed to move diagnostic testing beyond centralized laboratory environments and closer to real-world care settings. Its portable, autonomous format makes it suitable for use in primary care centres, pharmacies, and home-based environments, helping to accelerate clinical decision-making and improve access to diagnostic capabilities.

In addition to its rapid-testing performance, the device integrates connectivity and data transmission functionalitiesthat support use in telemedicine and remote monitoring environments. This connected architecture aligns with broader healthcare trends toward preventive, interoperable, and data-driven models of care.

The technology also offers strong potential as a multipurpose diagnostic platform, with possible applications in areas such as infectious disease detection, chronic disease monitoring, food safety, and veterinary diagnostics. The platform also incorporates patented technology for the detection of autoimmune conditions such as celiac disease, underscoring both its versatility and commercial potential.

As part of the development process, Eurecat contributed key enabling elements of the solution, including the single-use sample-analysis cartridge featuring a printed-electronics-based electrode, together with the portable reader, result visualization application, and data transmission systems. These contributions reinforce the platform’s scalability and support its pathway toward future market adoption.

Bioeclosion’s participation in 4YFN-MWC 2026 reflects the growing prominence of healthcare innovation within one of the world’s leading technology events. In a setting shaped by connectivity, artificial intelligence, and digital transformation, the company presented a solution aligned with several of the healthcare sector’s key innovation priorities, including rapid diagnostics, portability, connectivity, digital integration, and decentralized care.

“Our participation at 4YFN-MWC 2026 has been an excellent opportunity to showcase how next-generation biosensors can bring high-value diagnostic capabilities closer to the point of need,” said Dr. Jofre Ferrer-Dalmau, CEO of Bioeclosion. “It also provided a valuable platform to connect with potential investors, collaborators, and strategic stakeholders who share our ambition to accelerate the future of decentralized healthcare. At Bioeclosion, we are committed to advancing practical, quantitative, and connected diagnostic solutions that respond to the evolving needs of digital health.”

Through its participation at 4YFN-MWC 2026, Bioeclosion further reinforces its position as an innovator in rapid, decentralized diagnostics, advancing technologies designed to respond to the evolving needs of digital health and personalized medicine.

About Bioeclosion

Bioeclosion is a biotechnology company focused on the development of innovative diagnostic solutions based on biosensing technologies. The company is committed to advancing rapid, reliable, and accessible testing platforms that support the transformation of healthcare toward more decentralized, connected, and patient-centred models.

Sources

1. Bioeclosion — BioEclosion at Mobile World Congress 2026. Next-generation biosensors at 4YFN (Bioeclosion)
2. Fulls d’Enginyeria — Cinc novetats del MWC 2026 (fullsdenginyeria.cat)
3. WWWhat’s New — MWC 2026: la salud se cuela entre la conectividad y la IA (WWWhat’s new)
4. Europa Press — Eurecat presenta en el MWC una plataforma portátil que actúa como laboratorio de bolsillo (Europa Press)
5. Eurecat — Un laboratorio de bolsillo basado en biosensores que hace pruebas diagnósticas en minutos para detectar enfermedades como la celiaquía (Eurecat Centre Tecnològic)